https://www.selleckchem.com/pr....oducts/CP-690550.htm
Unit costs derived from official national sources (€, 2018). Over a life-time horizon, treating moderate-to-severe active ulcerative colitis with tofacitinib resulted in additional quality-adjusted life-years (QALYs) and lower total costs compared to vedolizumab (0.018; €6408), infliximab (biosimilar) (0.009; €3031), golimumab (0.042; €1988) and infliximab (originator) (0.009; €6724). Hence, tofacitinib was estimated to be dominant over all comparators. The results of the analysis suggest that in the Greek setting, tofacitinib could b
Like
Comment
Share
